143 related articles for article (PubMed ID: 37917641)
41. Selective inhibition of protein arginine methyltransferase 5 blocks initiation and maintenance of B-cell transformation.
Alinari L; Mahasenan KV; Yan F; Karkhanis V; Chung JH; Smith EM; Quinion C; Smith PL; Kim L; Patton JT; Lapalombella R; Yu B; Wu Y; Roy S; De Leo A; Pileri S; Agostinelli C; Ayers L; Bradner JE; Chen-Kiang S; Elemento O; Motiwala T; Majumder S; Byrd JC; Jacob S; Sif S; Li C; Baiocchi RA
Blood; 2015 Apr; 125(16):2530-43. PubMed ID: 25742700
[TBL] [Abstract][Full Text] [Related]
42. Validation of protein arginine methyltransferase 5 (PRMT5) as a candidate therapeutic target in the spontaneous canine model of non-Hodgkin lymphoma.
Sloan SL; Renaldo KA; Long M; Chung JH; Courtney LE; Shilo K; Youssef Y; Schlotter S; Brown F; Klamer BG; Zhang X; Yilmaz AS; Ozer HG; Valli VE; Vaddi K; Scherle P; Alinari L; Kisseberth WC; Baiocchi RA
PLoS One; 2021; 16(5):e0250839. PubMed ID: 33989303
[TBL] [Abstract][Full Text] [Related]
43.
Teh JLF; Cheng PF; Purwin TJ; Nikbakht N; Patel P; Chervoneva I; Ertel A; Fortina PM; Kleiber I; HooKim K; Davies MA; Kwong LN; Levesque MP; Dummer R; Aplin AE
Cancer Discov; 2018 May; 8(5):568-581. PubMed ID: 29496664
[TBL] [Abstract][Full Text] [Related]
44. Kinase inhibitor screening identifies CDK4 as a potential therapeutic target for melanoma.
Mahgoub T; Eustace AJ; Collins DM; Walsh N; O'Donovan N; Crown J
Int J Oncol; 2015 Sep; 47(3):900-8. PubMed ID: 26201960
[TBL] [Abstract][Full Text] [Related]
45. Loss of METTL3 attenuates blastic plasmacytoid dendritic cell neoplasm response to PRMT5 inhibition via IFN signaling.
Rethnam M; Tan DQ; Tan SH; Li J; Yokomori R; Li Y; Yang H; Sanda T; Suda T
Blood Adv; 2022 Sep; 6(18):5330-5344. PubMed ID: 35482445
[TBL] [Abstract][Full Text] [Related]
46. Prmt5 deficient mouse B cells display RNA processing complexity and slower colorectal tumor progression.
Zhou B; Chen N; Chen Z; Chen S; Yang J; Zheng Y; Shen L
Eur J Immunol; 2023 Oct; 53(10):e2250226. PubMed ID: 37389889
[TBL] [Abstract][Full Text] [Related]
47. Protein arginine methyltransferase 5 (PRMT5) activates WNT/β-catenin signalling in breast cancer cells via epigenetic silencing of DKK1 and DKK3.
Shailesh H; Siveen KS; Sif S
J Cell Mol Med; 2021 Feb; 25(3):1583-1600. PubMed ID: 33462997
[TBL] [Abstract][Full Text] [Related]
48. Differential expression, distinct localization and opposite effect on Golgi structure and cell differentiation by a novel splice variant of human PRMT5.
Sohail M; Zhang M; Litchfield D; Wang L; Kung S; Xie J
Biochim Biophys Acta; 2015 Oct; 1853(10 Pt A):2444-52. PubMed ID: 26151339
[TBL] [Abstract][Full Text] [Related]
49. Influence of cyclin D1 splicing variants expression on breast cancer chemoresistance via CDK4/CyclinD1-pRB-E2F1 pathway.
Wang J; Zhang J; Ma Q; Zhang S; Ma F; Su W; Zhang T; Xie X; Di C
J Cell Mol Med; 2023 Apr; 27(7):991-1005. PubMed ID: 36915230
[TBL] [Abstract][Full Text] [Related]
50. Efficacy of CDK4 inhibition against sarcomas depends on their levels of CDK4 and p16ink4 mRNA.
Perez M; Muñoz-Galván S; Jiménez-García MP; Marín JJ; Carnero A
Oncotarget; 2015 Dec; 6(38):40557-74. PubMed ID: 26528855
[TBL] [Abstract][Full Text] [Related]
51. Targeting PRMT5/Akt signalling axis prevents human lung cancer cell growth.
Zhang S; Ma Y; Hu X; Zheng Y; Chen X
J Cell Mol Med; 2019 Feb; 23(2):1333-1342. PubMed ID: 30461193
[TBL] [Abstract][Full Text] [Related]
52. Inhibition of Wee1, AKT, and CDK4 underlies the efficacy of the HSP90 inhibitor XL888 in an in vivo model of NRAS-mutant melanoma.
Haarberg HE; Paraiso KH; Wood E; Rebecca VW; Sondak VK; Koomen JM; Smalley KS
Mol Cancer Ther; 2013 Jun; 12(6):901-12. PubMed ID: 23538902
[TBL] [Abstract][Full Text] [Related]
53. Protein arginine methyltransferase 5 (PRMT5) inhibition induces lymphoma cell death through reactivation of the retinoblastoma tumor suppressor pathway and polycomb repressor complex 2 (PRC2) silencing.
Chung J; Karkhanis V; Tae S; Yan F; Smith P; Ayers LW; Agostinelli C; Pileri S; Denis GV; Baiocchi RA; Sif S
J Biol Chem; 2013 Dec; 288(49):35534-47. PubMed ID: 24189068
[TBL] [Abstract][Full Text] [Related]
54. Frequent genetic aberrations in the cell cycle related genes in mucosal melanoma indicate the potential for targeted therapy.
Xu L; Cheng Z; Cui C; Wu X; Yu H; Guo J; Kong Y
J Transl Med; 2019 Jul; 17(1):245. PubMed ID: 31358010
[TBL] [Abstract][Full Text] [Related]
55. Loss of CDKN2A expression is a frequent event in primary invasive melanoma and correlates with sensitivity to the CDK4/6 inhibitor PD0332991 in melanoma cell lines.
Young RJ; Waldeck K; Martin C; Foo JH; Cameron DP; Kirby L; Do H; Mitchell C; Cullinane C; Liu W; Fox SB; Dutton-Regester K; Hayward NK; Jene N; Dobrovic A; Pearson RB; Christensen JG; Randolph S; McArthur GA; Sheppard KE
Pigment Cell Melanoma Res; 2014 Jul; 27(4):590-600. PubMed ID: 24495407
[TBL] [Abstract][Full Text] [Related]
56. PRMT5 functionally associates with EZH2 to promote colorectal cancer progression through epigenetically repressing CDKN2B expression.
Yang L; Ma DW; Cao YP; Li DZ; Zhou X; Feng JF; Bao J
Theranostics; 2021; 11(8):3742-3759. PubMed ID: 33664859
[No Abstract] [Full Text] [Related]
57. Therapeutic effect of palbociclib in chondrosarcoma: implication of cyclin-dependent kinase 4 as a potential target.
Ouyang Z; Wang S; Zeng M; Li Z; Zhang Q; Wang W; Liu T
Cell Commun Signal; 2019 Feb; 17(1):17. PubMed ID: 30808351
[TBL] [Abstract][Full Text] [Related]
58. Functional, chemical genomic, and super-enhancer screening identify sensitivity to cyclin D1/CDK4 pathway inhibition in Ewing sarcoma.
Kennedy AL; Vallurupalli M; Chen L; Crompton B; Cowley G; Vazquez F; Weir BA; Tsherniak A; Parasuraman S; Kim S; Alexe G; Stegmaier K
Oncotarget; 2015 Oct; 6(30):30178-93. PubMed ID: 26337082
[TBL] [Abstract][Full Text] [Related]
59. Nuclear focal adhesion kinase induces APC/C activator protein CDH1-mediated cyclin-dependent kinase 4/6 degradation and inhibits melanoma proliferation.
Murphy JM; Jeong K; Ahn EE; Lim SS
J Biol Chem; 2022 Jun; 298(6):102013. PubMed ID: 35525274
[TBL] [Abstract][Full Text] [Related]
60. Targeting protein arginine methyltransferase 5 inhibits human hepatocellular carcinoma growth via the downregulation of beta-catenin.
Zhang B; Dong S; Li Z; Lu L; Zhang S; Chen X; Cen X; Wu Y
J Transl Med; 2015 Nov; 13():349. PubMed ID: 26541651
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]